Metastatic Non-Small Cell Lung Cancer Market to Surge with a Potential USD 45 Billion Valuation by 2032, Reveals New Comprehensive Analysis
January 24, 2024 10:28 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Non-Small Cell Lung Cancer - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's...
United States Clinical Oncology Next Generation Sequencing Research Report 2023: Market to Surpass $500 Million by 2030 - Advances in Personalized Medicine Aiding Growth
January 24, 2024 10:13 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "U.S. Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report By Workflow (NGS Pre-sequencing, NGS Sequencing, NGS...
Clinical Oncology Next Generation Sequencing Market Forecasts Rapid Growth with Advancements in Cancer Diagnostics
January 22, 2024 21:13 ET
|
Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Clinical Oncology Next Generation Sequencing Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The global...
Clinical Oncology Next Generation Sequencing Market Expected to Grow at a CAGR of 15.86% from 2023 to 2031
December 05, 2023 06:32 ET
|
InsightAce Analytic Pvt. LTd.
Jersey City, NJ, Dec. 05, 2023 (GLOBE NEWSWIRE) -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Clinical Oncology Next Generation Sequencing...
Clinical Oncology Next Generation Sequencing Global Market Report 2022: Featuring Key Players Thermo Fisher, Oxford Nanopore, F. Hoffmann-La Roche & Others
August 18, 2022 05:43 ET
|
Research and Markets
Dublin, Aug. 18, 2022 (GLOBE NEWSWIRE) -- The "Clinical Oncology Next Generation Sequencing Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering. The global...
Cornerstone Pharmaceuticals Announces Successful Completion of Phase 1b Clinical Trial for CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer
August 03, 2022 08:00 ET
|
Cornerstone Pharmaceuticals
CRANBURY, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael...
Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE
June 16, 2022 14:14 ET
|
Cornerstone Pharmaceuticals, Inc.
Cranbury, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael...
European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer
May 24, 2022 11:04 ET
|
Cornerstone Pharmaceuticals, Inc.
Cranbury, NJ, May 24, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael...
Rafael Pharmaceuticals, Inc. Announces Corporate Name Change to Cornerstone Pharmaceuticals, Inc.
May 19, 2022 09:00 ET
|
Cornerstone Pharmaceuticals, Inc.
Cranbury, NJ, May 19, 2022 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the development of rare cancer therapeutics, today announced that it is...
Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer
January 18, 2022 08:30 ET
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the growing field of cancer metabolism-based therapeutics, today...